Chemoradiation and immunotherapy for recurrent rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining standard chemoradiation with an immunotherapy drug (toripalimab) before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help remove the tumor more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has returned in the pelvis but has not spread to other organs.
- You have not had radiation therapy in the last 6 months.
- You have not received first-line chemotherapy for this recurrence.
- You are generally well enough to be up and about (ECOG 0 or 1).
- You have adequate organ function (kidney, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This trial tests whether giving radiation (with or without chemo) before surgery can help people whose rectal cancer has come back in the pelvis. It aims to make the tumor removable and improve outcomes.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Hear when a new Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.